RACURA ONCOLOGY

ASX Announcement

Racura to Present CPACS Phase 1 RC220 and Doxorubicin Data at the 2026 Global Cardio-Oncology Summit

- **Poster presentation accepted for the Global Cardio-Oncology Summit 2026 for the abstract, *"Cardioprotection & Anticancer Synergy (CPACS) – A Phase 1 Study of RC220 in Combination with Doxorubicin – Trial in Progress"***
- **Presentation will provide an update on the ongoing CPACS Phase 1 trial of RC220 with doxorubicin in patients with advanced solid tumours**

9 July 2026

Racura Oncology Limited ("Racura" or the "Company") is pleased to announce that it has been accepted to present at the Global Cardio-Oncology Summit 2026, to be held in Williamsburg (Virginia, USA) from 5 to 7 October 2026. The poster presentation will provide a clinical update on Racura's ongoing Cardioprotection & Anticancer Synergy (CPACS) Phase 1 study of RC220 in combination with doxorubicin in patients with advanced solid tumours.

Racura Oncology CEO and Managing Director, Dr Daniel Tillett, commented: *"Acceptance of our CPACS clinical study for presentation at the 2026 Global Cardio-Oncology Summit highlights the growing interest in RC220's potential to address cardiotoxicity, one of the key limitations of anthracycline-based cancer therapy. The study is evaluating if RC220 can be safely combined with doxorubicin to enhance anticancer activity and reduce cardiac injury. We look forward to updating the international cardio-oncology community on the progress of this important trial."*

A copy of the accepted abstract is attached to this release.

Significance of Anthracycline Cardiotoxicity

Anthracyclines remain central to many anticancer treatment regimens, but their clinical use is limited by irreversible cardiotoxicity. RC220 is a proprietary formulation developed by Racura of (E,E)-bisantrene, a clinically validated small molecule anticancer agent recently shown to act through G-quadruplex DNA and RNA binding, leading to potent silencing of c-MYC oncogene expression in preclinical cancer models.

RC220 in combination with doxorubicin has shown improved anticancer activity in human and murine tumour models and reduced anthracycline cardiotoxicity in human cardiomyocytes and multiple animal cardiac models.

CPACS Trial

The CPACS study is a multicentre, open-label, two-part Phase 1 trial in adult patients with advanced solid tumours, with enrolment ongoing in Australia, Hong Kong and will soon commence in South Korea. Part 1 is a Bayesian Optimal Interval (BOIN)-guided dose-escalation study of IV RC220 administered in combination with 60 mg/m² doxorubicin, preceded by monotherapy safety lead-in cycles of each agent.

The primary objective is to assess the safety and tolerability of the combination, with secondary objectives including maximum tolerated combined dose, pharmacokinetics, anti-tumour efficacy and exploratory cardioprotection biomarkers.

Following interim review, Part 2 will further evaluate safety, tolerability, preliminary anticancer activity and protection of cardiac function after anthracycline exposure.

– ENDS –

Cardioprotection & Anticancer Synergy (CPACS) – A Phase 1 Study of RC220 in Combination with Doxorubicin – Trial in Progress

Feroz Ahmad[1], Michelle Huh[1], Corli Merry[1], Mahmood Alam[2], Roland Ching Yu Leung[3], Daniel Tillett[1] and Marinella Messina[1]

[1]Racura Oncology, Sydney, Australia, [2]Cancer Care Foundation, Australia, [3]Queen Mary Hospital, Hong Kong.

Background

Anthracyclines remain an essential part of many anticancer protocols, but their clinical use is limited by irreversible cardiotoxicity. RC220 is a new formulation of (E,E)-bisantrene, a clinically proven small molecule anticancer agent that has recently been discovered to function via G-quadruplex DNA and RNA binding, resulting in silencing of c-MYC oncogene expression.

Preclinical studies of RC220 combined with doxorubicin have shown improved anticancer activity in murine tumor models, while also demonstrating reduced anthracycline cardiotoxicity in human cardiomyocytes, and murine and canine cardiac models.

Methods

This is a multicenter open-label, 2-part Phase 1 study in adult patients with advanced solid tumors recruiting patients in Australia, Hong Kong and South Korea.

Part 1 is a BOIN guided dose escalation study of IV RC220 administered in combination with 60 mg/m² doxorubicin, preceded by monotherapy cycles of each agent. The primary objective is the safety and tolerability of the combination, with secondary objectives to define the maximum tolerated combined dose (MTCD), PK, anti-tumor efficacy, and exploratory cardioprotection biomarkers.

Following an interim review, a Part 2 dose-expansion cohort will further assess safety, tolerability, preliminary anticancer activity, and protection of cardiac function (including GLS, cMRI, LVEF, CTRCD, cardiac biomarkers and $VO2_{peak}$) after anthracycline exposure in patients with solid tumors.

Results to date

The first cohort of three patients treated with RC220 at 40 mg/m² and doxorubicin at 60 mg/m² has been reviewed by the independent Safety Review Committee (SRC). The combination in up to five cycles was found to have an acceptable safety profile with no dose-limiting toxicity (DLT) or other significant safety concerns. Importantly, in preclinical studies, 40 mg/m² of RC220 was protective against doxorubicin-induced cardiotoxicity. The SRC has allowed escalation to the next RC220 dose level of 80 mg/m².

Conclusions

Initial safety findings at the starting dose level support continued dose escalation of RC220 in combination with doxorubicin, and enrolment is ongoing.

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily acts through G4-DNA and RNA binding, resulting in potent silencing of MYC, an important regulator of cancer growth. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety profile. Recent Racura discoveries have enabled composition of matter IP filings that may provide 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing RC220, a proprietary formulation of (E,E)-bisantrene, to address significant unmet needs across multiple oncology indications. Its clinical programs include a Phase 3 program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program combining RC220 with doxorubicin, where Racura aims to deliver both cardioprotection and enhanced anticancer activity for patients with solid tumours.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle. Racura is actively exploring partnerships, licence agreements and commercial merger and acquisition opportunities to accelerate global access to RC220 for patients with cancer. Learn more at www.racuraoncology.com.

For questions about this announcement or previous Racura Oncology announcements, please visit our Interactive Announcements page.

Racura encourages investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au